^
Association details:
| Biomarker: | EGFR T790M + PIK3CA H1047R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + AZD8835 (PI3K inhibitor, PIK3CA inhibitor, PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
Published date:
03/19/2021
Excerpt:
...co-treatment with PI3K pathway inhibitors was able to partially re-sensitise cells to osimertinib in both 2D (Fig. 5b) and 3D cultures (Supplementary Fig. 7c). Similar findings were observed in the PC9-T790M and HCC827 cell line models, where knock-in of the PIK3CAm resulted in resistance to osimertinib, which could be partially rescued by a co-treatment with PI3K pathway inhibitors (Fig. 5b), offering possible therapeutic strategies to combat TKI resistance driven by PIK3CA mutations.
DOI:
10.1038/s41467-021-22057-8
